Literature DB >> 11605080

SR141716, a CB1 receptor antagonist, decreases the sensitivity to the reinforcing effects of electrical brain stimulation in rats.

V Deroche-Gamonet1, M Le Moal, P V Piazza, P Soubrié.   

Abstract

RATIONALE: The endogenous cannabinoid system is thought to play a role in reinforcement processes.
OBJECTIVES: We tested the effects of five doses of the cannabinoid receptor 1 (CB1) antagonist SR141716 [0, 0.3, 1, 3 and 10 mg/kg intraperitoneal (IP)] on intracranial self-stimulation at the level of the median forebrain bundle (MFB). Self-stimulation was assessed 30 min and 210 min after SR141716 administration. We compared the effect of SR141716 with the effect of a decrease in the magnitude of stimulation (-100 microA) and the effects of a cocaine injection (1, 5 and 10 mg/kg IP).
METHODS: a protocol of rate-frequency curve for self-stimulation was applied. Two rate-frequency curves were established daily, 3 h apart. The frequency required to produce half-maximal performance (M50) and the maximal performance (RMax) were used as the parameters to characterize the rate-frequency functions.
RESULTS: SR141716 decreased the sensitivity to the electrical brain stimulation. SR141716 induced a shift to the right of the rate-frequency curve. This effect depended on the dose administered and the time after injection. Thirty minutes after the injection, 1, 3 and 10 mg/kg SR141716 induced a significant decrease in sensitivity to electrical stimulation, as shown by an elevation in the M50 value. RMax showed a tendency to decrease with increasing doses. At 210 min after administration, 3 and 10 mg/kg SR141716 maintained their decreasing effect on the sensitivity to the stimulation as shown by the significant increase of the M50, however, the maximal response was restored to the basal value. A decrease in self-stimulation intensity produced an effect comparable to the one observed 30 min after either 3 or 10 mg/kg SR141716, while cocaine (5 and 10 mg/kg) produced the opposite effect. Neither condition affected the rate-frequency curve measured 3 h later.
CONCLUSIONS: In accordance with recent observations, these experiments suggest that the endogenous cannabinoid system facilitates the perception or the effects of positive reinforcers. They also suggest that this neurochemical system could be a target of interest for treating psychopathologies implicating the reinforcing system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11605080     DOI: 10.1007/s002130100804

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  25 in total

1.  Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.

Authors:  Jason M Wiebelhaus; Travis W Grim; Robert A Owens; Matthew F Lazenka; Laura J Sim-Selley; Rehab A Abdullah; Micah J Niphakis; Robert E Vann; Benjamin F Cravatt; Jenny L Wiley; S Stevens Negus; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2014-11-14       Impact factor: 4.030

2.  Role of the endocannabinoid system in MDMA intracerebral self-administration in rats.

Authors:  Daniela Braida; Mariaelvina Sala
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

3.  The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food.

Authors:  Zoë D Thornton-Jones; Steven P Vickers; Peter G Clifton
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

4.  The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats.

Authors:  Anne B Need; Richard J Davis; Jesline T Alexander-Chacko; Brian Eastwood; Eyassu Chernet; Lee A Phebus; Dana K Sindelar; George G Nomikos
Journal:  Psychopharmacology (Berl)       Date:  2005-11-18       Impact factor: 4.530

5.  Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT1A receptor.

Authors:  Peter J McLaughlin; Julia E Jagielo-Miller; Emily S Plyler; Kerry K Schutte; V Kiran Vemuri; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2017-02-01       Impact factor: 4.530

6.  Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex.

Authors:  Francis Rodriguez Bambico; Noam Katz; Guy Debonnel; Gabriella Gobbi
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

Review 7.  The endocannabinoid system in brain reward processes.

Authors:  M Solinas; S R Goldberg; D Piomelli
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

8.  Effects of co-administration of 2-arachidonylglycerol (2-AG) and a selective µ-opioid receptor agonist into the nucleus accumbens on high-fat feeding behaviors in the rat.

Authors:  Kyle E Parker; Jordan G McCall; Sophia R McGuirk; Seema Trivedi; Dennis K Miller; Matthew J Will
Journal:  Brain Res       Date:  2015-06-19       Impact factor: 3.252

Review 9.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

10.  Reduced sensitivity to reward in CB1 knockout mice.

Authors:  Carles Sanchis-Segura; Brandon H Cline; Giovanni Marsicano; Beat Lutz; Rainer Spanagel
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.